Publications - Page 27 sur 43 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Fibrose pulmonaire - FPI 31/08/23
Clinical impact of TERT somatic mutation in telomerase-related gene mutation carriers after lung transplantation.

Ba I, Kannengiesser C, Mal H, Reynaud-Gaubert M, Cottin V, Hirschi S, Picard C, Borie R.

J Heart Lung Transplant. 2022 Sep;41(9):1207-1209.
Fibrose pulmonaire - FPI 31/08/23
Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.

Marinescu DC, Raghu G, Remy-Jardin M, Travis WD, Adegunsoye A, Beasley MB, Chung JH, Churg A, Cottin V, Egashira R, Fernández Pérez ER, Inoue Y, Johannson KA, Kazerooni EA, Khor YH, Lynch DA, Müller NL, Myers JL, Nicholson AG, Rajan S, Saito-Koyama R, Troy L, Walsh SLF, Wells AU, Wijsenbeek MS, Wright JL, Ryerson CJ.

Chest. 2022 Sep;162(3):614-629.
Fibrose pulmonaire - FPI 31/08/23
Ethnographic survey of patients and caregiver’s life journey in idiopathic pulmonary fibrosis.

Ahmed L, Bergot E, Prévot G, Cottin V.

Respir Med Res. 2022 Oct 1;83:100955.
Fibrose pulmonaire - FPI 31/08/23
Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.

Cottin V, Spagnolo P, Bonniaud P, Dalon F, Nolin M, Kirchgässler KU, Van Ganse E, Belhassen M.

Respir Med Res. 2022 Nov 23;83:100951.
Fibrose pulmonaire - FPI 31/08/23
[Secondary pulmonary alveolar proteinosis in a transplant patient].

Chevereau-Choquet M, Marchand-Adam S, Mankikian J, Bergemer-Fouquet AM, Eymieux S, Flament T.

Rev Mal Respir. 2022 Nov;39(9):795-800.
Fibrose pulmonaire - FPI 31/08/23
GLPG1205 for idiopathic pulmonary fibrosis: a Phase 2 randomised placebo-controlled trial.

Strambu IR, Seemayer CA, Fagard LMA, Ford PA, Van der Aa TAK, de Haas-Amatsaleh AA, Modgill V, Santermans E, Sondag EN, Helmer EG, Maher TM, Costabel U, Cottin V.

Eur Respir J. 2022 Nov 3:2201794.
Fibrose pulmonaire - FPI 31/08/23
Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants Supports Functional Roles of MUC5B and DSP in Idiopathic Pulmonary Fibrosis.

Borie R, Cardwell J, Konigsberg IR, Moore CM, Zhang W, Sasse SK, Gally F, Dobrinskikh E, Walts A, Powers J, Brancato J, Rojas M, Wolters PJ, Brown KK, Blackwell TS, Nakanishi T, Richards JB, Gerber AN, Fingerlin TE, Sachs N, Pulit SL, Zappala Z, Schwartz DA, Yang IV.

Am J Respir Crit Care Med. 2022 Nov 15;206(10):1259-1270.
Fibrose pulmonaire - FPI 31/08/23
Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective.

Papiris SA, Kannengiesser C, Borie R, Kolilekas L, Kallieri M, Apollonatou V, Ba I, Nathan N, Bush A, Griese M, Dieude P, Crestani B, Manali ED.

Diagnostics (Basel). 2022 Nov 23;12(12):2928.
Fibrose pulmonaire - FPI 31/08/23
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis.

Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM.

J Comp Eff Res. 2022 Dec 20.
Fibrose pulmonaire - FPI 31/08/23
MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis.

Van der Vis JJ, Prasse A, Renzoni EA, Stock CJW, Caliskan C, Maher TM, Bonella F, Borie R, Crestani B, Petrek M, Wuyts WA, Wind AE, Molyneaux PL, Grutters JC, van Moorsel CHM.

Respirology. 2022 Dec 26.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Clinical impact of TERT somatic mutation in telomerase-related gene mutation carriers after lung transplantation.

Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.

Ethnographic survey of patients and caregiver’s life journey in idiopathic pulmonary fibrosis.

Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.

[Secondary pulmonary alveolar proteinosis in a transplant patient].

GLPG1205 for idiopathic pulmonary fibrosis: a Phase 2 randomised placebo-controlled trial.

Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants Supports Functional Roles of MUC5B and DSP in Idiopathic Pulmonary Fibrosis.

Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective.

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis.

MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis.